Skip to main content
. 2021 Sep 24;71(5):1063–1074. doi: 10.1007/s00262-021-03060-w

Fig. 7.

Fig. 7

The best change from baseline in sum of the longest target lesion diameter per patient receiving lenvatinib plus immune checkpoint inhibitors (a) or receiving lenvatinib monotherapy (b). Assessed with Response Evaluation Criteria in Solid Tumors v1.1 in patients with image measurements before and after treatment